Literature DB >> 24152685

Prognostic nomograms to predict oncological outcome of thyroid cancers.

K Alok Pathak1, Andrea Mazurat, Pascal Lambert, Thomas Klonisch, Richard W Nason.   

Abstract

CONTEXT: Thyroid cancers represent a conglomerate of diverse histological types with equally variable prognosis. There is no reliable prognostic model to predict the risks of relapse and death for different types of thyroid cancers.
OBJECTIVE: The purpose of this study was to build prognostic nomograms to predict individualized risks of relapse and death of thyroid cancer within 10 years of diagnosis based on patients' prognostic factors.
DESIGN: Competing risk subhazard models were used to develop prognostic nomograms based on the information on individual patients in a population-based thyroid cancer cohort followed up for a median period of 126 months. Analyses were conducted using R version 2.13.2. The R packages cmprsk10, Design, and QHScrnomo were used for modeling, developing, and validating the nomograms for prediction of patients' individualized risks of relapse and death of thyroid cancer.
SETTING: This study was performed at CancerCare Manitoba, the sole comprehensive cancer center for a population of 1.2 million. PATIENTS: Participants were a population-based cohort of 2306 consecutive thyroid cancers observed in 2296 patients in the province of Manitoba, Canada, during 1970 to 2010. MAIN OUTCOME MEASURES: Outcomes were discrimination (concordance index) and calibration curves of nomograms.
RESULTS: Our cohort of 570 men and 1726 women included 2155 (93.4%) differentiated thyroid cancers. On multivariable analysis, patient's age, sex, tumor histology, T, N, and M stages, and clinically or radiologically detectable posttreatment gross residual disease were independent determinants of risk of relapse and/or death. The individualized 10-year risks of relapse and death of thyroid cancer in the nomogram were predicted by the total of the weighted scores of these determinants. The concordance indices for prediction of thyroid cancer-related deaths and relapses were 0.92 and 0.76, respectively. The calibration curves were very close to the diagonals.
CONCLUSIONS: We have successfully developed prognostic nomograms for thyroid cancer with excellent discrimination (concordance indices) and calibration.

Entities:  

Mesh:

Year:  2013        PMID: 24152685     DOI: 10.1210/jc.2013-2318

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  15 in total

1.  Establishment and validation of a nomogram model for predicting the survival probability of differentiated thyroid carcinoma patients: a comparison with the eighth edition AJCC cancer staging system.

Authors:  Ruyi Zhang; Mei Xu; Xiangxiang Liu; Miao Wang; Qiang Jia; Shen Wang; Xiangqian Zheng; Xianghui He; Chao Huang; Yaguang Fan; Heng Wu; Ke Xu; Dihua Li; Zhaowei Meng
Journal:  Endocrine       Date:  2021-04-06       Impact factor: 3.633

2.  Updated American Joint Committee on Cancer/Tumor-Node-Metastasis Staging System for Differentiated and Anaplastic Thyroid Cancer (Eighth Edition): What Changed and Why?

Authors:  R Michael Tuttle; Bryan Haugen; Nancy D Perrier
Journal:  Thyroid       Date:  2017-05-19       Impact factor: 6.568

Review 3.  Differentiated and anaplastic thyroid carcinoma: Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

Authors:  Nancy D Perrier; James D Brierley; R Michael Tuttle
Journal:  CA Cancer J Clin       Date:  2017-11-01       Impact factor: 508.702

4.  Validation and Comparison of Nomograms in Predicting Disease-Specific Survival for Papillary Thyroid Carcinoma.

Authors:  Brian Hung-Hin Lang; Carlos K H Wong
Journal:  World J Surg       Date:  2015-08       Impact factor: 3.352

5.  Adolescent and young adult cancer survival.

Authors:  Denise Riedel Lewis; Nita L Seibel; Ashley Wilder Smith; Margaret R Stedman
Journal:  J Natl Cancer Inst Monogr       Date:  2014-11

6.  BRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer.

Authors:  Fei Wang; Shihua Zhao; Xiaopei Shen; Guangwu Zhu; Rengyun Liu; David Viola; Rossella Elisei; Efisio Puxeddu; Laura Fugazzola; Carla Colombo; Barbara Jarzab; Agnieszka Czarniecka; Alfred K Lam; Caterina Mian; Federica Vianello; Linwah Yip; Garcilaso Riesco-Eizaguirre; Pilar Santisteban; Christine J O'Neill; Mark S Sywak; Roderick Clifton-Bligh; Bela Bendlova; Vlasta Sýkorová; Yangang Wang; Mingzhao Xing
Journal:  J Clin Oncol       Date:  2018-08-02       Impact factor: 44.544

7.  A novel RNA sequencing-based risk score model to predict papillary thyroid carcinoma recurrence.

Authors:  Jingni He; Zhong Tian; Xu Yao; Baiyu Yao; Yuan Liu; Jiapeng Yang
Journal:  Clin Exp Metastasis       Date:  2019-12-02       Impact factor: 5.150

8.  Using the American Thyroid Association Risk-Stratification System to Refine and Individualize the American Joint Committee on Cancer Eighth Edition Disease-Specific Survival Estimates in Differentiated Thyroid Cancer.

Authors:  Sana A Ghaznavi; Ian Ganly; Ashok R Shaha; Crystal English; Jonathan Wills; R Michael Tuttle
Journal:  Thyroid       Date:  2018-08-02       Impact factor: 6.568

9.  The age factor in survival of a population cohort of well-differentiated thyroid cancer.

Authors:  Andrea Mazurat; Andrea Torroni; Jane Hendrickson-Rebizant; Harbinder Benning; Richard W Nason; K Alok Pathak
Journal:  Endocr Connect       Date:  2013-09-23       Impact factor: 3.335

Review 10.  Mechanisms of therapeutic resistance in cancer (stem) cells with emphasis on thyroid cancer cells.

Authors:  Sabine Hombach-Klonisch; Suchitra Natarajan; Thatchawan Thanasupawat; Manoj Medapati; Alok Pathak; Saeid Ghavami; Thomas Klonisch
Journal:  Front Endocrinol (Lausanne)       Date:  2014-03-25       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.